Skip to main content
Premium Trial:

Request an Annual Quote

Decode s Q1 Revenues Rise 6 Percent As Losses Swell 20 Percent

NEW YORK, May 2 (GenomeWeb News) - Decode Genetics yesterday reported an approximately 6-percent increase in first-quarter revenues despite escalating losses.


Decode's revenues for the quarter ended March 31 rose to $10.1 million from $9.5 million year over year.


Decode said that R&D expenses for the first quarter swelled to $14.9 million from $8.3 million year over year.


The company's net loss swelled 20 percent to $20.3 million from $16.9 million in the year-ago period. Decode attributed the increase to higher R&D costs related to clinical trials and preclinical development work in the company's lead drug-development programs.


As of March 31, Decode had $140 million in cash and cash investments.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.